ProCE Banner Activity

ARRAY-520-216: Phase II Trial of Carfilzomib With or Without Filanesib in R/R MM

Slideset Download
Conference Coverage
Carfilzomib plus filanesib vs single-agent carfilzomib associated with longer median PFS for patients with pretreated R/R MM.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen